Merck & Co. Earnings Call Transcripts
Fiscal Year 2026
-
The acquisition of Terns Pharmaceuticals for $6.7 billion adds TERN-701, a next-generation CML therapy with best-in-class potential, to the hematology pipeline. The deal is expected to close in Q2 2026, driving long-term growth and leveraging existing commercial strengths.
-
The company is launching over 20 new human health products and expects animal health revenues to double by the mid-2030s. Key late-stage pipeline assets target major unmet needs, with strong growth anticipated post-KEYTRUDA exclusivity loss. Diversification in oncology, cardiometabolic, and vaccine portfolios is central to the next decade’s strategy.
-
A diverse late-stage pipeline and disciplined business development have positioned the company for over $70 billion in commercial opportunities by the mid-2030s. Key product launches, accelerated clinical programs, and strategic acquisitions support confidence in managing the Keytruda LOE and sustaining long-term growth.
Fiscal Year 2025
-
Q4 2025 revenue grew 5% to $16.4B, led by oncology and new launches, while animal health also performed strongly. 2026 guidance calls for 1–3% revenue growth, with $70B in potential commercial opportunity by mid-2030s and continued investment in pipeline and business development.
-
Key highlights include a $5B+ opportunity for a novel influenza antiviral, strong uptake and expansion for WINREVAIR in PAH, and robust progress in oral PCSK9 and immunology pipelines. Oncology launches and external funding deals are supporting a broad, high-impact late-stage portfolio.
-
Key pipeline programs advance with phase 3 starts in pulmonary hypertension, strong growth for WINREVAIR, and a promising oral PCSK9. Ophthalmology and immunology assets target large unmet needs, while lifecycle management for KEYTRUDA and new HIV anchors are prioritized.
-
Multiple milestones were highlighted, including the Cidara acquisition for a long-acting antiviral, strong progress in PAH and rare disease programs, and rapid advancement of new assets in ophthalmology and HIV. The pipeline features transformative therapies with broad regulatory and market interest.
-
The acquisition brings a first-in-class, long-acting antiviral for influenza, targeting a large unmet need in high-risk populations. The $9.2 billion deal is expected to drive significant growth, with CD388 offering over $5 billion in commercial potential and leveraging existing infrastructure.
-
Panelists highlighted rising vaccine hesitancy, the enduring trust in healthcare professionals, and the importance of local voices and robust communication. Innovations in R&D, AI, and global partnerships are shaping access and future vaccine development, with cancer vaccines and rapid-response platforms seen as key growth areas.
-
MK-0616 (Enlisted) demonstrated robust, durable LDL-C lowering of up to 59.7% with a placebo-like safety profile and high adherence, positioning it as a leading oral add-on therapy for cardiovascular risk reduction. Regulatory filings are planned for early 2026, with significant commercial potential projected for the cardiometabolic and respiratory portfolio.
-
Q3 saw 4% revenue growth to $17.3B, led by oncology, animal health, and new launches. Guidance for 2025 is $64.5–$65B in revenue and $8.93–$8.98 EPS, with strong pipeline momentum and new product approvals offsetting vaccine and LOE headwinds.
-
A major transformation is underway, shifting from reliance on a single product to a diversified launch strategy with over 20 new molecular entities and a $50B+ commercial opportunity by the mid-2030s. Key growth drivers include robust oncology, HIV, ophthalmology, and animal health pipelines, proactive pricing strategies, and global expansion, with strong clinical progress in WINREVAIR and ADCs.
-
Management highlighted a robust pipeline with 20 launches underway, aiming for over $50B in revenue by the mid-2030s. KEYTRUDA growth is expected to continue with new indications and a subcutaneous formulation, while diversification in oncology and non-oncology assets, business development, and disciplined financial strategy underpin long-term growth.
-
Q2 revenue reached $15.8B, with strong oncology and animal health growth offset by a sharp GARDASIL decline in China. Guidance for 2025 remains at $64.3–$65.3B revenue and $8.87–$8.97 EPS, with a $3B cost optimization program to fund pipeline expansion and new launches.
-
A robust late-stage HIV pipeline is advancing, featuring daily, weekly, and monthly oral regimens for both treatment and PrEP. Key programs show strong efficacy, safety, and patient preference for long-acting options, with a commercial opportunity exceeding $5 billion by the mid-2030s.
-
The acquisition brings a first-in-class COPD therapy with strong clinical and commercial momentum, expanding the cardiopulmonary portfolio and supporting long-term growth. The $10B deal is expected to be accretive over time, with robust patent protection and significant market opportunity.
-
Leadership outlined a transformative period with nearly 20 new launches across diverse therapeutic areas and a projected $50B+ revenue opportunity by the 2030s. Ongoing policy discussions, manufacturing pivots, and robust pipelines in cardiometabolic, oncology, and animal health support a strong growth outlook.
-
The event highlighted a diversified oncology strategy, major clinical advances in subcutaneous pembrolizumab, KRAS G12C, and ADCs, and a robust late-stage pipeline. Commercial plans target broad adoption and value-driven pricing, with a focus on innovation and global expansion.
-
The event highlighted robust pipeline expansion, strategic manufacturing shifts, and a diversified approach to business development. Key launches like WINREVAIR and the subcutaneous Keytruda formulation are expected to drive growth, while margin management and a $50B+ pipeline revenue target underpin long-term confidence.
-
The meeting highlighted strong financial growth, a robust and diversified pipeline, and major investments in manufacturing and R&D. All board nominees and management proposals were approved, while shareholder proposals received low support. Key risks discussed included regulatory changes and product demand in China.
-
Leaders highlighted ongoing policy uncertainty, especially around MFN and IRA, and detailed Keytruda’s continued growth, upcoming LOE, and robust late-stage pipeline. GARDASIL remains strong outside China, and the company is advancing innovation in oncology and vaccines.
-
Q1 revenue reached $15.5B, with strong growth in oncology, animal health, and new launches, offset by a Gardasil sales decline in China. Full-year guidance is maintained, with robust pipeline progress and strategic U.S. manufacturing investments supporting long-term growth.
-
Strong growth is projected through oncology, animal health, and new launches, with a robust late-stage pipeline and strategic business development. Key products like Winrevair, Welireg, and Keytruda Sub-Q are advancing, while global expansion and innovation remain central.
-
The event highlighted robust revenue growth, a diversified and expanding late-stage pipeline, and significant investments in business development. Key launches and data readouts are expected in 2024–2025, with oncology, vaccines, and HIV as major growth drivers. Confidence in long-term growth remains strong.
Fiscal Year 2024
-
Strong Q4 and 2024 growth was driven by oncology, animal health, and new launches, offsetting Gardasil's China headwinds. 2025 guidance reflects continued robust performance ex-China, with a diversified pipeline and major late-stage assets supporting long-term growth.
-
The conference highlighted optimism for policy improvements, robust vaccine and oncology portfolios, and strong global growth prospects. New launches like Capvaxive, clesrovimab, and Winrevair are set to drive future performance, while a diverse and expanding pipeline underpins long-term confidence.
-
Revenue guidance was raised with strong growth outside China, and major commercial opportunities identified in oncology, cardiometabolic, and immunology. The pipeline features promising oncology assets, a robust oral PCSK9 program, differentiated obesity strategies, and next-gen vaccines and HIV PrEP candidates.
-
Management outlined a robust oncology pipeline, rapid drug development capabilities, and strategic global expansion for vaccines. Subq Keytruda and next-gen ADCs are positioned for broad impact, while Gardasil's growth will rely on new markets and innovations.
-
Q3 delivered strong growth across human and animal health, driven by oncology and new launches. Pipeline momentum is robust, with key assets advancing in immunology, MASH, and cardiovascular disease. GARDASIL and KEYTRUDA remain growth drivers, with strategic focus on new indications and geographies.
-
Q3 revenue rose 4% to $16.7B, led by Keytruda and new launches, while Gardasil declined in China but grew elsewhere. 2024 guidance was narrowed, with solid growth expected in 2025 despite headwinds from Gardasil China and immunology expirations.
-
Strong international growth and pipeline expansion were highlighted, with Keytruda and Gardasil driving revenue and new launches like WINREVAIR diversifying the portfolio. Strategic focus includes emerging markets, innovative access, and robust business development, aiming for significant growth and diversification by the mid-2030s.
-
Management highlighted robust pipeline growth, confidence in Gardasil’s global expansion, and a disciplined, science-driven approach to business development. Winrevair’s launch is on track, with European and future China opportunities, while key pipeline assets in IBD, pneumococcal, and HIV are advancing.
-
Q2 2024 saw strong revenue and EPS growth, led by oncology and new product launches. Guidance was raised despite Gardasil shipment challenges in China, with robust global demand and pipeline progress supporting long-term confidence.
-
Strong progress across oncology, cardiometabolic, immunology, and animal health portfolios, with robust phase II/III pipelines and successful product launches like WINREVAIR. Strategic M&A, early partnerships, and innovation in key assets support growth into the 2030s.